Allele and genotype frequencies of polymorphic cytochromes P4502D6, 2C19 and 2E1 in Aborigines from Western Australia

Pharmacogenetics

Volumn 11, Issue 1, 2001, Pages 69-76

  Griese, E U ^a   Ilett, K F ^a   Kitteringham, N R ^a   Eichelbaum, M ^a   Powell, H ^a   Spargo, R M ^a   LeSouef, P N ^a   Musk, A W ^a   Minchin, R F ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Australian Aborigine; CYP2C19; CYP2D6; CYP2E1; Genetic polymorphism

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1;

ABORIGINE; ARTICLE; AUSTRALIA; CAUCASIAN; ETHNIC DIFFERENCE; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC DRIFT; GENETIC HETEROGENEITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NATURAL SELECTION; PHENOTYPE; POPULATION GENETICS; PRIORITY JOURNAL;

ALLELES; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIXED FUNCTION OXYGENASES; OCEANIC ANCESTRY GROUP; POLYMORPHISM, GENETIC; WESTERN AUSTRALIA;

EID: 0035133641     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200102000-00008     Document Type: Article

References (54)

1. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19
2. Importance of genetic factors in the regulation of diazepam metabolism: Relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype
3. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine
4. Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry
5. Ethnic and genetic determinants of omeprazole disposition and effect
6. Cytochrome P4502E1 genotypes, alcoholism, and alcoholic cirrhosis in Han Chinese and Atayal natives of Taiwan
7. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes
8. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population
9. Cytochrome P4502E1 inducibility and hydroxyethyl radical formation among alcoholics
10. The genetic polymorphism of debrisoquine/sparteine metabolism-clinical aspects
11. Gloriously deceitful, and a virgin
12. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations
13. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population
14. Detection of CYP2C19 alleles *1, *2 and *3 by multiplex polymerase chain reaction
15. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a west African population
16. Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects
17. Effect of CYP2C polymorphisms on the pharmacokinetics of phenytoin in Japanese patients with epilepsy
18. Genetic polymorphisms in 5′-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene
19. The human CYP2E1 gene and lung cancer: DraI and RsaI restriction fragment length polymorphisms in a Finnish study population
20. Genetic polymorphisms of CYP2E1, GSTM1, and GSTT1; environmental factors and risk of oral cancer
21. Acetylation phenotype and genotype in Aboriginal leprosy patients from the north-west region of Western Australia
22. Genetic polymorphisms in glutathione S-transferase M1 and T1 in an Australian Aborigine population
23. Genetic analysis of the Chinese cytochrome P4502D locus: Characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation
24. Proguanil disposition and toxicity in malaria patients from Vanuatu with high frequencies of CYP2C19 mutations
25. Cytochrome P450IIE1 genetic polymorphisms, racial variation, and lung cancer risk
26. Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms
27. Cytochrome P450 isozymes and antiepileptic drug interactions
28. Fundamentals and applications of pharmacogenetics for the clinical laboratory
29. Association between restriction fragment length polymorphism of the human cytochrome P450IIE1 gene and susceptibility to alcoholic liver cirrhosis
30. A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: Association with diminished debrisoquine hydroxylase activity
31. Genetic polymorphism of drug metabolising enzymes in African populations: Implications for the use of neuroleptics and antidepressants
32. Molecular mechanisms of genetic polymorphisms of drug metabolism
33. Endogenous codeine and morphine in poor and extensive metabolisers of the CYP2D6 (debrisoquine/sparteine) polymorphism
34. Cytochrome P4502C9: An enzyme of major importance in human drug metabolism
35. Themes in the prehistory of tropical Australia
36. Genetic polymorphism of cytochrome P4502E1 in a Swedish population. Relationship to incidence of lung cancer
37. Genetic polymorphism of cytochrome P4502E1 and risk of alcoholic liver disease in Caucasians
38. The hypoalgesic effect of tramadol in relation to CYP2D6
39. Bioactivation of halogenated hydrocarbons by cytochrome P4502E1
40. Dapsone N-acetylation, metoprolol alpha-hydroxylation, and S-mephenytoin 4-hydroxylation polymorphisms in an Indonesian population: A cocktail and extended phenotyping assessment trial
41. Rapid detection of CYP2D6 null alleles by long distance- and multiplex-polymerase chain reaction
42. Genetic polymorphisms of cytochrome P4502E1 related to the development of alcoholic liver disease
43. Hepatic messenger RNA contents of cytochrome P4502E1 in patients with different P4502E1 genotypes
44. Restriction fragment length polymorphism of the human CYP2E1 (cytochrome P450IIE1) gene and susceptibility to lung cancer: Possible relevance to low smoking exposure
45. Human ethanol-inducible P450IIE1: Complete gene sequence, promoter characterization, chromosome mapping, and cDNA-directed expression
46. Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations
47. PstI and RsaI RFLPs in complete linkage disequilibrium at the CYP2E gene
48. Different regulation and expression of the human CYP2E1 gene due to the RsaI polymorphism in the 5′-flanking region
49. The relationship between phenytoin pharmacokinetics and the CYP2C19 genotype in Japanese epileptic patients
50. Pharmacogenetics
51. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele